A Phase 3 interventional study of APL-2 in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Apellis Pharmaceuticals, Inc.. Completed at 30 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-21.
Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Hemoglobinuria, Paroxysmal with a site in Thailand — 2 open to participants now, 4 under way, 3 of them phase 3. Hemoglobinuria, Paroxysmal · Thailand.
Among the 10 studies in Hemoglobinuria, Paroxysmal with a site in Thailand, this one is the 7th largest by enrollment, is one of 2 that started in 2019, is one of 8 in phase 3, and was the 4th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →2 of the 10 studies in Hemoglobinuria, Paroxysmal with a site in Thailand are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in Thailand, Brazil, Canada and 18 more countries
Ages 18+
Apellis Pharmaceuticals, Inc. · Sites in Thailand, United States, Czechia and 6 more countries
Ages 12–17
A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2019.
This study's enrollment of 53 is above the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 83 across the 10 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 5 most frequent:
This study is registered under Apellis Pharmaceuticals, Inc., one of the names counted as Biogen. Under that name alone:
Apellis Pharmaceuticals, Inc. is the lead sponsor of 28 studies on the registry; 3 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Biogen has 6 studies filed under Hemoglobinuria, Paroxysmal — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Hemoglobinuria, Paroxysmal with a site in Thailand, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluation of the Efficacy and Safety of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Concomitant use of any of the following medications is prohibited if not on a stable regimen for the time period indicated below prior to screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: APL-2
Complement (C3) Inhibitor
Number of Subjects Who Achieved Hemoglobin (Hb) Stabilization
The Hb stabilization was defined as avoidance of a \>1 gram per deciliter (g/dL) decrease in Hb concentration from Baseline in the absence of transfusion through Week 26.
Time frame: From Baseline (Day 1) up to Week 26
Change From Baseline in Lactate Dehydrogenase (LDH) Concentration At Week 26
The LDH concentration was analyzed using an analysis of covariance (ANCOVA) model with a last observation carried forward (LOCF) and a baseline observation carried forward (BOCF) approach for handling missing data. Baseline was defined as average of measurements prior to first dose of pegcetacoplan or on or prior to randomization of SoC. Post baseline missing values are imputed using multiple imputation method with Markov Chain Mont Carlo method.
Time frame: Baseline (Day 1) and Week 26
Number of Subjects With an Hb Response in the Absence of Transfusions
An Hb response was defined as a =\>1 g/dL increase in Hb from baseline at Week 26.
Time frame: Baseline and Week 26
Change From Baseline in Absolute Reticulocyte Count (ARC) at Week 26
Blood samples were collected via direct venipuncture at the specific time points to determine ARC. Baseline was defined as average of measurements prior to first dose of pegcetacoplan or on or prior to randomization of SoC. Post baseline missing values are imputed using multiple imputation method with Markov Chain Mont Carlo method.
Time frame: Baseline and Week 26
Change From Baseline in Hb Concentration at Week 26
Baseline was defined as average of measurements prior to first dose of pegcetacoplan or on or prior to randomization of SoC. Post baseline missing values are imputed using multiple imputation method with Markov Chain Mont Carlo method.
Time frame: Baseline and Week 26
Percentage of Subjects Who Received Transfusion or Decrease of Hb >2 g/dL From Baseline
Transfusion refers to any transfusion of PRBC, leukocyte-depleted red blood cells (LDPRC), leukocyte poor packed red blood cell (LPRC), leukocyte poor blood (LPB) or whole blood.
Time frame: At Week 26
Percentage of Subjects With Transfusion Avoidance
Transfusion avoidance was defined as the percentage of subjects who did not require a transfusion during the RCP. Transfusion refers to any transfusion of PRBC, LDPRC, LPRC, LPB or whole blood.
Time frame: At Week 26
Number of PRBC Units Transfused From Baseline Through Week 26
The number of units of PRBC transfusions was estimated. In one transfusion subjects received one or more units.
Time frame: Up to Week 26
Change From Baseline in Functional Assessment of Chronic Illness Therapy- (FACIT-Fatigue) Scale Score at Week 26
The FACIT-Fatigue Scale is a 13-item Likert scaled instrument that is self-administered by the subjects during clinic visits. Subjects were presented with 13 statements and asked to indicate their responses as it applied to the past 7 days. The 5 possible responses are "Not at all" (0), "A little bit" (1), "Somewhat" (2), "Quite a bit" (3), and "Very much" (4). With 13 statements, the total score has a range of 0 to 52. The higher score corresponded to a higher quality of life. Baseline is defined as average of measurements prior to first dose of pegcetacoplan or on or prior to randomization of SoC. Post baseline missing values are imputed using multiple imputation method with Markov Chain Mont Carlo method.
Time frame: Baseline and Week 26
Percentage of Subjects With Hb Normalization Levels at Week 26
Normalization of Hb levels defined as \>= 1x LLN at Week 26 in the absence of transfusion. Transfusion refers to any transfusion of PRBC, LDPRC, LPRC, LPB or whole blood.
Time frame: Baseline and Week 26
Percentage of Subjects With LDH Normalization at Week 26
The LDH normalization was defined as LDH \<= 1xupper limit of normal (ULN) of normal range at week 26 in the absence of transfusion. Transfusion refers to any transfusion of PRBC, LDPRC, LPPRC, LPRC, LPB or whole blood.
Time frame: At Week 26
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) 30-item Core Quality of Life Questionnaire (QLQ-C30) Scores at Week 26
The EORTC QLQ-C30 questionnaire (version 3.0) consisted of 30 questions comprised of both multi-item scales and single-item measures to assess overall quality of life in subjects. Questions were designated by functional scales, symptom scales, and global subject QOL/overall perceived health status. For the first 28 questions the 4 possible responses are "Not at all' (1), 'A little' (2), 'Quite a bit' (3) and 'Very much' (4). For the remaining 2 questions the response is requested on a 7-point scale from 1 ('Very poor') to 7 ('Excellent'). Each scale has a range of 0% - 100%. A high scale score represents a higher response level. Baseline is defined as average of measurements prior to first dose of pegcetacoplan or on or prior to randomization of SoC. Post baseline missing values are imputed using multiple imputation method with Markov Chain Mont Carlo method.
Time frame: Baseline and Week 26
Change From Baseline in Linear Analog Assessment (LASA) Scales Score at Week 26
The LASA consisted of 3 items asking respondents to rate their perceived level of functioning. Specific domains include activity level, ability to carry out daily activities, and an item for overall QOL. Their level of functioning was reported on a 0-100 scale with 0 representing "As low as could be" and 100 representing "As high as could be".
Time frame: Baseline and Week 26
Percentage of Subjects With ARC Normalization
Absolute reticulocyte count normalization is defined as ARC \< 1x ULN of the gender-specific normal range at week 26 in the absence of transfusion. Subjects who received a transfusion or withdraw from study or escaped from SoC to pegcetacoplan treatment group or lost to follow up without providing efficacy data at Week 26 were classified as non-responders. Transfusion refers to any transfusion of PRBC, LDPRC, LPRC, LPB or whole blood.
Time frame: At Week 26
Number of Subjects With Failure of Hb Stabilization
Hb stabilization is defined as avoidance of a \>1 g/dL decrease in Hb levels from baseline through Week 26 in the absence of transfusion. Transfusion refers to any transfusion of PRBC, LDPRC, LPRC, LPB or whole blood.
Time frame: Up to Week 26
Time to First PRBC Transfusion
Time to first-on-study PRBC transfusions during RCP were reported. Here NA indicates not estimable.
Time frame: Up to Week 26
This study was conducted in subjects with paroxysmal nocturnal hemoglobinuria (PNH) at 22 investigational sites. The study consisted of a screening period (up to 4 weeks), followed by a randomized controlled period (RCP) (26 weeks). All subjects who completed RCP rolled over into a separate open-label, long-term extension study (APL2-307) or completed the safety follow-up (34 weeks).
| Milestone | Pegcetacoplan | Standard of Care |
|---|---|---|
| Started | 35 | 18 |
| Soc to pegcetacoplan (escape therapy) | 0 | 11 |
| Completed | 33 | 17 |
| Not completed | 2 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Death | 1 | 1 |
The Hb stabilization was defined as avoidance of a \>1 gram per deciliter (g/dL) decrease in Hb concentration from Baseline in the absence of transfusion through Week 26.
| Participants | Pegcetacoplan | Standard of Care |
|---|---|---|
| Number of Subjects Who Achieved Hemoglobin (Hb) Stabilization | 30 | 0 |
The LDH concentration was analyzed using an analysis of covariance (ANCOVA) model with a last observation carried forward (LOCF) and a baseline observation carried forward (BOCF) approach for handling missing data. Baseline was defined as average of measurements prior to first dose of pegcetacoplan or on or prior to randomization of SoC. Post baseline missing values are imputed using multiple imputation method with Markov Chain Mont Carlo method.
| Units/Liter (U/L) | Pegcetacoplan | Standard of Care |
|---|---|---|
| Change From Baseline in Lactate Dehydrogenase (LDH) Concentration At Week 26 | -1870.47 ± 100.971 | -400.09 ± 312.988 |
An Hb response was defined as a =\>1 g/dL increase in Hb from baseline at Week 26.
| Participants | Pegcetacoplan | Standard of Care |
|---|---|---|
| Number of Subjects With an Hb Response in the Absence of Transfusions | 25 | 1 |
Blood samples were collected via direct venipuncture at the specific time points to determine ARC. Baseline was defined as average of measurements prior to first dose of pegcetacoplan or on or prior to randomization of SoC. Post baseline missing values are imputed using multiple imputation method with Markov Chain Mont Carlo method.
| 10^9 cells/L | Pegcetacoplan | Standard of Care |
|---|---|---|
| Change From Baseline in Absolute Reticulocyte Count (ARC) at Week 26 | -123.26 ± 9.164 | -19.44 ± 25.209 |
Baseline was defined as average of measurements prior to first dose of pegcetacoplan or on or prior to randomization of SoC. Post baseline missing values are imputed using multiple imputation method with Markov Chain Mont Carlo method.
| g/dL | Pegcetacoplan | Standard of Care |
|---|---|---|
| Change From Baseline in Hb Concentration at Week 26 | 2.94 ± 0.383 | 0.27 ± 0.759 |
Transfusion refers to any transfusion of PRBC, leukocyte-depleted red blood cells (LDPRC), leukocyte poor packed red blood cell (LPRC), leukocyte poor blood (LPB) or whole blood.
| percentage of subjects | Pegcetacoplan | Standard of Care |
|---|---|---|
| Percentage of Subjects Who Received Transfusion or Decrease of Hb >2 g/dL From Baseline | 11.4 | 100 |
Transfusion avoidance was defined as the percentage of subjects who did not require a transfusion during the RCP. Transfusion refers to any transfusion of PRBC, LDPRC, LPRC, LPB or whole blood.
| percentage of subjects | Pegcetacoplan | Standard of Care |
|---|---|---|
| Percentage of Subjects With Transfusion Avoidance | 91.4 | 5.6 |
The number of units of PRBC transfusions was estimated. In one transfusion subjects received one or more units.
| PRBC transfusions | Pegcetacoplan | Standard of Care |
|---|---|---|
| Number of PRBC Units Transfused From Baseline Through Week 26 | 0.0 (0 to 19) | 3.0 (0 to 13) |
The FACIT-Fatigue Scale is a 13-item Likert scaled instrument that is self-administered by the subjects during clinic visits. Subjects were presented with 13 statements and asked to indicate their responses as it applied to the past 7 days. The 5 possible responses are "Not at all" (0), "A little bit" (1), "Somewhat" (2), "Quite a bit" (3), and "Very much" (4). With 13 statements, the total score has a range of 0 to 52. The higher score corresponded to a higher quality of life. Baseline is defined as average of measurements prior to first dose of pegcetacoplan or on or prior to randomization of SoC. Post baseline missing values are imputed using multiple imputation method with Markov Chain Mont Carlo method.
| scores on a scale | Pegcetacoplan | Standard of Care |
|---|---|---|
| Change From Baseline in Functional Assessment of Chronic Illness Therapy- (FACIT-Fatigue) Scale Score at Week 26 | 7.78 ± 1.210 | 3.26 ± 2.113 |
Normalization of Hb levels defined as \>= 1x LLN at Week 26 in the absence of transfusion. Transfusion refers to any transfusion of PRBC, LDPRC, LPRC, LPB or whole blood.
| percentage of subjects | Pegcetacoplan | Standard of Care |
|---|---|---|
| Percentage of Subjects With Hb Normalization Levels at Week 26 | 45.7 | 0 |
The LDH normalization was defined as LDH \<= 1xupper limit of normal (ULN) of normal range at week 26 in the absence of transfusion. Transfusion refers to any transfusion of PRBC, LDPRC, LPPRC, LPRC, LPB or whole blood.
| percentage of subjects | Pegcetacoplan | Standard of Care |
|---|---|---|
| Percentage of Subjects With LDH Normalization at Week 26 | 65.7 | 0 |
The EORTC QLQ-C30 questionnaire (version 3.0) consisted of 30 questions comprised of both multi-item scales and single-item measures to assess overall quality of life in subjects. Questions were designated by functional scales, symptom scales, and global subject QOL/overall perceived health status. For the first 28 questions the 4 possible responses are "Not at all' (1), 'A little' (2), 'Quite a bit' (3) and 'Very much' (4). For the remaining 2 questions the response is requested on a 7-point scale from 1 ('Very poor') to 7 ('Excellent'). Each scale has a range of 0% - 100%. A high scale score represents a higher response level. Baseline is defined as average of measurements prior to first dose of pegcetacoplan or on or prior to randomization of SoC. Post baseline missing values are imputed using multiple imputation method with Markov Chain Mont Carlo method.
| scores on a scale | Pegcetacoplan | Standard of Care |
|---|---|---|
| Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) 30-item Core Quality of Life Questionnaire (QLQ-C30) Scores at Week 26 | 18.90 ± 2.909 | -2.85 ± 5.703 |
The LASA consisted of 3 items asking respondents to rate their perceived level of functioning. Specific domains include activity level, ability to carry out daily activities, and an item for overall QOL. Their level of functioning was reported on a 0-100 scale with 0 representing "As low as could be" and 100 representing "As high as could be".
| scores on a scale | Pegcetacoplan | Standard of Care |
|---|---|---|
| Change From Baseline in Linear Analog Assessment (LASA) Scales Score at Week 26 | 50.39 ± 9.062 | -5.39 ± 17.689 |
Absolute reticulocyte count normalization is defined as ARC \< 1x ULN of the gender-specific normal range at week 26 in the absence of transfusion. Subjects who received a transfusion or withdraw from study or escaped from SoC to pegcetacoplan treatment group or lost to follow up without providing efficacy data at Week 26 were classified as non-responders. Transfusion refers to any transfusion of PRBC, LDPRC, LPRC, LPB or whole blood.
| percentage of subjects | Pegcetacoplan | Standard of Care |
|---|---|---|
| Percentage of Subjects With ARC Normalization | 60.0 | 5.6 |
Hb stabilization is defined as avoidance of a \>1 g/dL decrease in Hb levels from baseline through Week 26 in the absence of transfusion. Transfusion refers to any transfusion of PRBC, LDPRC, LPRC, LPB or whole blood.
| Participants | Pegcetacoplan | Standard of Care |
|---|---|---|
| Number of Subjects With Failure of Hb Stabilization | 4 | 18 |
Time to first-on-study PRBC transfusions during RCP were reported. Here NA indicates not estimable.
| weeks | Pegcetacoplan | Standard of Care |
|---|---|---|
| Time to First PRBC Transfusion | NA (NA to NA) | 7.000 (4.143 to 10.286) |
Collected over Treatment-emergent adverse events were reported from the first dose of study medication and for up to 8 weeks after the last dose of study medication, approximately 34 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Overall Pegcetacoplan | 1/46 (2.2%) | 6/46 (13%) | 35/46 (76.1%) |
| Standard of Care | 1/18 (5.6%) | 3/18 (16.7%) | 12/18 (66.7%) |
| Event | Overall Pegcetacoplan | Standard of Care |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/46 | 1/18 |
| Bone marrow failureBlood and lymphatic system disorders | 0/46 | 1/18 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/46 | 1/18 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 0/46 | 1/18 |
| Metabolic acidosisMetabolism and nutrition disorders | 0/46 | 1/18 |
| Septic shockInfections and infestations | 1/46 | 1/18 |
| Herpes virus infectionInfections and infestations | 0/46 | 1/18 |
| Pulmonary tuberculosisInfections and infestations | 0/46 | 1/18 |
| Urinary tract infectionInfections and infestations | 0/46 | 1/18 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/46 | 1/18 |
| Event | Overall Pegcetacoplan | Standard of Care |
|---|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 6/46 | 2/18 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 6/46 | 0/18 |
| Upper respiratory tract infectionInfections and infestations | 1/46 | 2/18 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/46 | 0/18 |
| DizzinessNervous system disorders | 5/46 | 0/18 |
| PyrexiaGeneral disorders | 4/46 | 0/18 |
| HeadacheNervous system disorders | 4/46 | 0/18 |
| EcchymosisSkin and subcutaneous tissue disorders | 3/46 | 0/18 |
| ErythemaSkin and subcutaneous tissue disorders | 3/46 | 0/18 |
| Viral infectionInfections and infestations | 3/46 | 0/18 |
The intent-to-treat (ITT) set included all subjects assigned to treatment.
| Age, Continuous(years) | Pegcetacoplan | Standard of Care | Total |
|---|---|---|---|
| Mean | 42.2 ± 12.70 | 49.1 ± 15.64 | 44.5 ± 14.00 |
| Age, Customized(Participants) | Pegcetacoplan | Standard of Care | Total |
|---|---|---|---|
| <65 years | 33 | 14 | 47 |
| >=65 and <75 years | 2 | 4 | 6 |
| Sex: Female, Male(Participants) | Pegcetacoplan | Standard of Care | Total |
|---|---|---|---|
| Female | 16 | 8 | 24 |
| Male | 19 | 10 | 29 |
| Ethnicity (NIH/OMB)(Participants) | Pegcetacoplan | Standard of Care | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 2 | 14 |
| Not Hispanic or Latino | 23 | 16 | 39 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Pegcetacoplan | Standard of Care | Total |
|---|---|---|---|
| Black or African American | 2 | 0 | 2 |
| American Indian or Alaska Native | 9 | 2 | 11 |
| Asian | 23 | 16 | 39 |
| Other | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2019 to primary completion in Jun 2021, 21 months.
Results were first posted in Oct 2022, 1 year 3 months after primary completion.
Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 21 months is close to that.
Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegcetacoplan
Apellis Pharmaceuticals, Inc. →